[go: up one dir, main page]

WO2005037865A3 - Ztnfr14, A TUMOR NECROSIS FACTOR RECEPTOR - Google Patents

Ztnfr14, A TUMOR NECROSIS FACTOR RECEPTOR Download PDF

Info

Publication number
WO2005037865A3
WO2005037865A3 PCT/US2004/034375 US2004034375W WO2005037865A3 WO 2005037865 A3 WO2005037865 A3 WO 2005037865A3 US 2004034375 W US2004034375 W US 2004034375W WO 2005037865 A3 WO2005037865 A3 WO 2005037865A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptides
necrosis factor
factor receptor
tumor necrosis
ztnfr14
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/034375
Other languages
French (fr)
Other versions
WO2005037865A2 (en
Inventor
Brian A Fox
James L Holloway
Paul O Sheppard
Stacey R Dillon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymogenetics Inc
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Priority to JP2006535407A priority Critical patent/JP2008500804A/en
Priority to EP04795522A priority patent/EP1673390A2/en
Priority to CA002542482A priority patent/CA2542482A1/en
Publication of WO2005037865A2 publication Critical patent/WO2005037865A2/en
Publication of WO2005037865A3 publication Critical patent/WO2005037865A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Novel tumor necrosis factor receptor (TNFR) polypeptides, polynucleotides encoding the polypeptides, antibodies and related compositions and methods are disclosed. The polypeptides may be used for detecting ligand, as well as agonists and antagonists. The polypeptides, polynucleotides and antibodies may also be used in methods that modulate tumor growth, metastasis, and immunity such as separating resting from stimulated immune cells.
PCT/US2004/034375 2003-10-16 2004-10-18 Ztnfr14, A TUMOR NECROSIS FACTOR RECEPTOR Ceased WO2005037865A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2006535407A JP2008500804A (en) 2003-10-16 2004-10-18 ztnfr14, tumor necrosis factor receptor
EP04795522A EP1673390A2 (en) 2003-10-16 2004-10-18 Ztnfr14, A TUMOR NECROSIS FACTOR RECEPTOR
CA002542482A CA2542482A1 (en) 2003-10-16 2004-10-18 Ztnfr14, a tumor necrosis factor receptor

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US51169803P 2003-10-16 2003-10-16
US60/511,698 2003-10-16
US61955204P 2004-10-18 2004-10-18
US60/619,652 2004-10-18

Publications (2)

Publication Number Publication Date
WO2005037865A2 WO2005037865A2 (en) 2005-04-28
WO2005037865A3 true WO2005037865A3 (en) 2005-08-04

Family

ID=34468001

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/034375 Ceased WO2005037865A2 (en) 2003-10-16 2004-10-18 Ztnfr14, A TUMOR NECROSIS FACTOR RECEPTOR

Country Status (1)

Country Link
WO (1) WO2005037865A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
GB0410021D0 (en) * 2004-05-05 2004-06-09 Celltech R&D Ltd A protein involved in cancer
JP2009536022A (en) * 2006-04-19 2009-10-08 ジェネンテック・インコーポレーテッド Novel gene disruption and related compositions and methods
WO2008140565A2 (en) * 2006-11-08 2008-11-20 Zymogenetics, Inc. Use of tumor necrosis factor receptor 14 antagonists for treating psoriasis
KR20100053607A (en) 2007-08-03 2010-05-20 패시트 바이오테크 코포레이션 Therapeutic use of anti-tweak receptor antibodies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999004001A1 (en) * 1997-07-21 1999-01-28 Zymogenetics, Inc. Tumor necrosis factor receptor ztnfr-5
WO1999011790A1 (en) * 1997-09-04 1999-03-11 Zymogenetics, Inc. Tumor necrosis factor receptor ztnfr-6
WO2001098353A2 (en) * 2000-06-20 2001-12-27 Incyte Genomics, Inc. Secreted proteins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999004001A1 (en) * 1997-07-21 1999-01-28 Zymogenetics, Inc. Tumor necrosis factor receptor ztnfr-5
WO1999011790A1 (en) * 1997-09-04 1999-03-11 Zymogenetics, Inc. Tumor necrosis factor receptor ztnfr-6
WO2001098353A2 (en) * 2000-06-20 2001-12-27 Incyte Genomics, Inc. Secreted proteins

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BODMER J-L ET AL: "The molecular architecture of the TNF superfamily", TIBS TRENDS IN BIOCHEMICAL SCIENCES, ELSEVIER PUBLICATION, CAMBRIDGE, EN, vol. 27, no. 1, 1 January 2002 (2002-01-01), pages 19 - 26, XP004332356, ISSN: 0968-0004 *
DATABASE EMBL 16 September 2003 (2003-09-16), XP002317141, retrieved from EBI Database accession no. AK000591 *
DATABASE EMBL 17 September 2003 (2003-09-17), XP002317143, retrieved from EBI Database accession no. BC008788 *
DATABASE EMBL 7 June 2002 (2002-06-07), XP002317186, retrieved from EBI Database accession no. AX402506 *
DATABASE UniProt 1 December 2001 (2001-12-01), XP002317185, retrieved from EBI Database accession no. Q96HA4 *
DATABASE UniProt 1 October 2000 (2000-10-01), XP002317142, retrieved from EBI Database accession no. Q9NWV0 *

Also Published As

Publication number Publication date
WO2005037865A2 (en) 2005-04-28

Similar Documents

Publication Publication Date Title
IL166659A0 (en) Nogo receptor antagonists
EP2526968A3 (en) Nogo receptor antagonists
WO2006060513A3 (en) Toll like receptor 3 antagonists, methods and uses
PL380274A1 (en) Nogo receptor antagonists
IL142103A0 (en) Receptor based antagonists and methods of making and using
WO2004039951A3 (en) Il-1 receptor based antagonists and methods of making and using
WO2004078938A3 (en) Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
WO2002082076A3 (en) Renal cell carcinoma tumor markers
WO2003042344A3 (en) Apo2 ligand/trail formulations
WO2002002636A3 (en) Membrane associated protein zupari
UA87106C2 (en) Nogo receptor binding protein
WO2003068941A3 (en) Modulation of immune response by non-peptide binding stress response polypeptides
WO2002062999A3 (en) Proteins and nucleic acids encoding same
TW200801039A (en) Separation methods
WO2004112703A3 (en) Interleukin-21 analogs
WO2001038352A3 (en) Methods of inhibiting metastasis
WO2005037865A3 (en) Ztnfr14, A TUMOR NECROSIS FACTOR RECEPTOR
WO2003018798A3 (en) G-protein coupled receptor and dna sequences thereof
PL376219A1 (en) Stabilized, solid-state polypeptide particles
WO2005063813A3 (en) Process for the production of tumor necrosis factor-binding proteins
WO2008140565A3 (en) Use of tumor necrosis factor receptor 14 antagonists for treating psoriasis
EP1212340A4 (en) 29 human cancer associated proteins
WO2002068594A3 (en) Opiate receptors
AU2003277575A1 (en) Novel fprl1 ligands and use thereof
WO2005020956A3 (en) Microparticles

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2542482

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006535407

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004795522

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004795522

Country of ref document: EP